Conference report: Eplerenone in patients with acute STEMI without heart failure
Source: PharmaLive Area: News PharmaLive has reported on results from the REMINDER trial, which evaluated eplerenone in the early treatment of acute ST-segment elevation myocardial infarction (STEMI). These results were presented at the 62nd Annual Scientific Session of the American College of Cardiology. The REMINDER study included 1,012 patients with acute STEMI without a history of heart failure (HF) or an ejection fraction of
Conclusions BBs differ within the class in so many ways that it is not only logical but also practical for real-life clinical practice that experts in the field make a list of the compelling indications for individual BBs. Time has come to incorporate our knowledge about BBs into a new approach of presenting these useful and very individual drugs. PMID: 32418526 [PubMed - as supplied by publisher]
Coronary artery disease is the most common cause of heart failure (HF) in developed countries. Ventricular tachycardia (VT)/ventricular fibrillation (VF) are the most common causes of sudden cardiac death (SCD) in patients with postmyocardial infarction (MI) HF. Pharmacologic therapies have been shown to reduce mortality levels in these patients, and most of those medications involve the sympathetic nervous system and the renin-angiotensin-aldosterone pathway, such as beta-blockers, angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists.
Coronary artery disease (CAD) is the most common cause of heart failure (HF) in developed countries. Ventricular tachycardia (VT)/ventricular fibrillation (VF) are the most frequent causes of sudden cardiac death (SCD) in patients with post-myocardial infarction (MI) HF. Pharmacological therapies have been shown to reduce mortality in these patient, and most of those medications involve the sympathetic nervous system and the renin-angiotensin-aldosterone pathway, such as beta blockers, angiotensin-converting-enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs) and aldosterone antagonists.
Conclusions: Preventive VT ablation before ICD implantation did not reduce mortality or hospitalization for arrhythmia or worsening heart failure during 1 year of follow-up when compared to the deferred ablation strategy. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02501005. PMID: 32000514 [PubMed - as supplied by publisher]
Therapies that target scar formation after myocardial infarction (MI) could prevent ensuing heart failure or death from ventricular arrhythmias. We have previously shown that recombinant human platelet-derived growth factor-AB (rhPDGF-AB) improves cardiac function in a rodent model of MI. To progress clinical translation, we evaluated rhPDGF-AB treatment in a clinically relevant porcine model of myocardial ischemia-reperfusion. Thirty-six pigs were randomized to sham procedure or balloon occlusion of the proximal left anterior descending coronary artery with 7-day intravenous infusion of rhPDGF-AB or vehicle. One month aft...
ConclusionTakotsubo cardiomyopathy may develop in critically ill cardiac diseases but are often underdiagnosed. Careful echocardiographic examination is needed to unveil these “hidden” TC.
This article is protected by copyright. All rights reserved
AbstractAimsThe aim of this study was to determine the incidence, predictors, and short ‐term and long‐term outcomes associated with in‐hospital sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) collectively termed ventricular arrhythmia (VA) in the heart failure (HF) patients.Methods and resultsThe HEart function Assessment Registry Trial in Saudi Arabia (HEARTS registry) is a prospective national registry of patients with chronic HF from18 tertiary care hospitals across Saudi Arabia. Diagnosis of HF was in accordance with American Heart Association/European Society of Cardiology definition cr...
This article provides a review of the aforementioned mechanisms of arrhythmogenesi s in heart failure; the role and impact of HF therapy such as cardiac resynchronization therapy (CRT), including the role, if any, of CRT-P and CRT-D in preventing VAs; the utility of both non-invasive parameters as well as multiple implant-based parameters for telemonitoring in HF; and the effect o f left ventricular assist device implantation on VAs.
AbstractAtrial high rate episodes (AHREs), also termed, subclinical atrial tachyarrhythmias or subclinical atrial fibrillation (AF) are an important cardiovascular condition. Advancement in implantable cardiac devices such as pacemakers or internal cardiac defibrillators has enabled the continuous assessment of atrial tachyarrhythmias in patients with an atrial lead. Patients with device-detected AHREs are at an elevated risk of stroke and may have unmet anticoagulation needs. While the benefits of oral anticoagulation for stroke prevention in patients with clinical AF are well recognised, it is not known whether the same ...